2024
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Schmit N, Topazian H, Natama H, Bellamy D, Traoré O, Somé M, Rouamba T, Tahita M, Bonko M, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo M, Lopez F, Charles G, McCain K, Ouedraogo J, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill A, Ewer K, Ghani A, Winskill P. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet Infectious Diseases 2024, 24: 465-475. PMID: 38342107, DOI: 10.1016/s1473-3099(23)00816-2.Peer-Reviewed Original ResearchDisability-adjusted life yearsClinical malariaMalaria vaccineClinical casesVaccine introductionVaccinated childrenVaccine efficacyYears of follow-upPhase 2b trialPhase 3 trialSub-Saharan AfricaSurrogate of protectionIncremental costAntibody titresPublic health impactSerum Institute of IndiaBill &Cost-effectiveness ratioChildren aged 2Dose pricesMalaria deathsMelinda Gates FoundationNIHR Oxford Biomedical Research CentreFollow-upUK Medical Research Council
2021
Combining malaria vaccination with chemoprevention: a promising new approach to malaria control
Greenwood B, Cairns M, Chaponda M, Chico R, Dicko A, Ouedraogo J, Phiri K, ter Kuile F, Chandramohan D. Combining malaria vaccination with chemoprevention: a promising new approach to malaria control. Malaria Journal 2021, 20: 361. PMID: 34488784, PMCID: PMC8419817, DOI: 10.1186/s12936-021-03888-8.Peer-Reviewed Original ResearchConceptsIntermittent preventive treatmentMalaria controlMalaria chemopreventionMalaria vaccinationMalaria vaccinePreventive treatmentPost-discharge malaria chemopreventionSeasonal malaria chemopreventionManagement of childrenPrevention of malariaMass drug administrationSickle cell diseaseMalaria elimination programmeClinical malariaSevere malariaSevere anemiaMalaria deathsRecent trialsCell diseaseChemopreventive regimenDrug AdministrationClinical situationsVaccinationElimination programChemopreventionEthical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Tindana P, de Haan F, Mokuolu O, Guissou R, Bolarinwa O, Ouedraogo J, Tou F, Boon W, Moors E, Dondorp A, Dhorda M, Amaratunga C, Cheah P. Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol. Wellcome Open Research 2021, 6: 75. PMID: 34458588, PMCID: PMC8378406, DOI: 10.12688/wellcomeopenres.16065.1.Peer-Reviewed Original ResearchArtemisinin combination therapyCombination therapyQualitative research methodsViews of stakeholdersDepth interviewsPosition issuesMarket-related issuesCommunity membersNational Malaria Control ProgrammeGlobal malaria deathsArtemisinin combination treatmentSoutheast AsiaGroup discussionsNational regulatory authoritiesMalaria control programmesResearch methodsAfricaACT resistanceMalaria deathsMalaria treatmentStudy protocolMalaria prevalenceAntimalarial medicinesCombination treatmentStakeholders